RxDoctor Payments Data

Tierney Russell, APRN

Family · Little Rock, ARNPI 1184324113

Payments from drug & device makers

$1,813in general payments, 2019–2025

Across 92 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$444
  • AstraZeneca$327
  • Pfizer$277
  • Lilly USA, LLC$147
  • Amgen$131
  • Dexcom, Inc.$119
  • plus $368 from 9 others

What the payments were for

  • Food & beverage$1,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,813 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$51,931
Medicare patients
429
Services billed
1,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$12,985
JardianceEmpagliflozin21$12,337
Zolmitriptan12$4,736
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,817
Levothyroxine Sodium88$1,024
Atorvastatin Calcium94$927
Duloxetine Hcl26$827
Raloxifene Hcl17$820
Clarithromycin33$814
Albuterol Sulfate HfaAlbuterol Sulfate31$695
Ventolin HfaAlbuterol Sulfate12$654
Prednisone93$636
Doxazosin Mesylate11$463
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav51$445
Omeprazole17$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$12,98512 claims
Boehringer IngelheimJardiance$16$12,33721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.

Other family in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →